Prophylaxis and treatment of recurrent hepatitis B after liver transplantation.
Chronic hepatitis B virus (HBV) infection is the leading cause of end-stage liver disease in Asia. The results of liver transplantation in these patients have significantly improved to a level comparable to those of other recipients as a result of the rapid evolution in the strategies of prevention and treatment of recurrent hepatitis B over the past decade. Hepatitis B immune globulin (HBIG) and lamivudine, either alone or in combination, are effective in preventing reinfection, but the most cost-effective dosing regimen with optimum efficacy without the prohibitive cost remains to be determined, an issue that is particularly relevant to liver transplant centers with serious financial constraints in Asia. The idea of active immunization is attractive, but the results have been conflicting to date. The newer nucleoside analogs appear most promising, and a combination of two or more antiviral agents is likely to represent the future strategy of choice in the prophylaxis and treatment of recurrent hepatitis B after liver transplantation.
Lo
Chung-Mau
CM
Centre for the Study of Liver Disease and the Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China. chungmlo@hkucc.hku.hk.
Fan
Sheung-Tat
ST
Liu
Chi-Leung
CL
Lai
Ching-Lung
CL
Wong
John
J
D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006509:Hepatitis B / Q000517:prevention & control* / Q000601:surgery* / Q000628:therapy; D006801:Humans; D007114:Immunization; D007136:Immunoglobulins / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D011315:Preventive Medicine / Q000379:methods*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D055502:Secondary Prevention
D000998:Antiviral Agents; D007136:Immunoglobulins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine